Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

This Phase 1/2a study is testing a new oral cancer drug called IPG7236 in people with advanced solid tumors that have not responded to standard treatments. IPG7236 is a targeted therapy taken as a pill. The first part of the study tests different doses to find the safest and most effective amount; the second part focuses on specific cancer types including kidney cancer, triple-negative breast cancer, head and neck cancer, and melanoma. You may be eligible if: - You are 18 years of age or older - You have an advanced or metastatic solid tumor confirmed by biopsy or cytology - Your cancer has progressed or you are not eligible for standard treatments - You have at least one measurable tumor on imaging - You have a life expectancy of at least 3 months - Your ECOG performance status is 0 or 1 - You can swallow pills - Your blood counts, kidney, and liver function are adequate You may NOT be eligible if: - You have cancer of the brain or spinal cord as the primary site - You have active hepatitis B or C, or HIV infection - You are pregnant or breastfeeding - You have received recent chemotherapy, immunotherapy, or other anti-cancer drugs (within specified time periods) - You have a prolonged QT interval on your ECG - You have a serious uncontrolled illness - You have had a prior malignancy within the last 3 years (with some exceptions) Talk to your doctor to see if this trial is right for you.